Healthcare Industry News: Sagent Pharmaceuticals
News Release - November 29, 2007
Sagent Pharmaceuticals Launches Full-Line of Prefilled 6 mg and 12 mg Adenosine SyringesAdenosine launch marks the first commercial product launch from Sagent's pipeline of more than 200 products
Sagent first non-branded, specialty injectables source to market full-line of adenosine prefilled syringes.
SCHAUMBURG, Ill., Nov. 29 (HSMN NewsFeed) -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company today announced that it has launched a full-line of prefilled, ready-to-use, 6 mg and 12 mg adenosine syringes. Launch of the adenosine syringe line marks Sagent's initial launch from its pipeline of more than 200 products. Sagent is currently the only non-branded specialty injectables source marketing both 6 mg and 12 mg adenosine syringes. IMS data indicates that the 2006 domestic adenosine syringe market was approximately $17 million. Adenosine syringes are manufactured for Sagent by Gland Pharma.
"For Sagent, this approval represents the initiation of our commercial activities as we continue to rapidly advance our extensive pipeline of more than 200 specialty products," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "For the medical community, the prefilled adenosine syringe line represents another safe, effective and easily delivered treatment option for patients in need of an antiarrhythmic. This innovative product is in line with Sagent's mission to deliver an extensive portfolio of injectable products that is customer-focused and fulfills the evolving needs of patients."
Adenosine injection, USP, is the generic equivalent of Astellas Pharma U.S., Inc.'s Adenocard®, an antiarrhythmic commonly used in the treatment of parosysmal supraventricular tachycardia, a rhythm disturbance of the heart, in critical care situations. Adenosine works by slowing the electrical conduction in the heart, slowing heart rate of normalizing heart rhythm. The most common adverse effects may include facial flushing, shortness of breath and chest pressure. These are generally self-limiting and resolve within a few seconds. Less common adverse effects include transient or prolonged asystole, varying degrees of AV block, premature ventricular contractions, premature atrial contractions and bradycardia.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific focus on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.
For more information about Sagent, please visit http://www.sagentpharma.com.
About Gland Pharma Ltd.
Established in 1978 as an exclusive facility for Small Volume Parenterals (SVPs), Gland Pharma has developed into a progressive and quality conscious organization serving the pharmaceutical needs of more than 25 countries across the globe. Gland Pharma has world-class and world-scale facilities for injectables. Gland Pharma's research and development operation develops niche products from active pharmaceutical ingredient to finished dosages. Adenosine is one of many approved abbreviated new drug applications from the Gland Pharma's growing portfolio.
For more information about Gland Pharma, please visit http://www.glandpharma.com
Source: Sagent Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.